BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:ASP5834 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of ASP5834\, from ClinicalTrials.gov estimat
 es.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07094204-2361@assetmemo.bio
DTSTAMP:20261121T004551Z
DTSTART;VALUE=DATE:20281130
DTEND;VALUE=DATE:20281201
SUMMARY:ASP5834: Phase 1 readout est. (NCT07094204)
DESCRIPTION:ASP5834\, phase 1\, Non-Small Cell Lung Cancer.\nStudy: A Study
  to Find a Suitable Dose of ASP5834 in Adults With Solid Tumors\nEstimated
  primary completion: 30 November 2028. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/asp5834#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT07094204
URL:https://assetmemo.bio/drug/asp5834#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
